Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 17/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044688 | 0.91 | ADK (0.56) | ADKSLC29A1MTORRAB9AABL1 | |
| SCHEMBL18589204 | 0.89 | ADK (0.56) | ADKSLC29A1MTORRAB9ALCK | |
| SCHEMBL4659175 | 0.86 | ADK (0.50) | ADKSLC29A1MTORRAB9AABL1 | |
| SCHEMBL23733113 | 0.86 | ADK (0.56) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL4659181 | 0.86 | ADK (0.56) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL29484542 | 0.85 | ADK (0.54) | ADKSLC29A1MTORRAB9ALCK | |
| SCHEMBL16236390 | 0.85 | ADK (0.54) | ADKSLC29A1MTORRAB9ALCK | |
| SCHEMBL18044589 | 0.85 | ADK (0.53) | ADKSLC29A1MTORRAB9ALCK | |
| SCHEMBL398720 | 0.85 | ADK (0.57) | ADKSLC29A1MTORRAB9ALCK | |
| SCHEMBL398110 | 0.85 | ADK (0.57) | ADKSLC29A1MTORRAB9ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | ADK 282/4885SLC29A1 3249/4885MTOR 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.